Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression.

The Journal of pathology - 1 Mar 2026

Chui Michael Herman, Brown David N, Reis-Filho Jorge S, Ellenson Lora Hedrick, Weigelt Britta

Abstract excerpt

Intratumor heterogeneity of ERBB2 amplification/HER2 overexpression is frequently observed in ERBB2-amplified high-grade endometrial carcinoma (HG-EC) and contributes to anti-HER2 therapy resistance. To elucidate the molecular pathogenesis and evolutionary trajectory of HER2-heterogeneous HG-ECs, we performed next-generation sequencing of spatially distinct HER2-negative (HER2-) and HER2-positive (HER2+) tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Exome Sequencing

Share to Gene Amplification

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasm Grading

Source

Open in PubMed Open full text

Identifiers

PMID: 41496508
DOI: 10.1002/path.70014
PMCID: PMC13499629

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression.PMID 41496508Read ↗

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Semantic proximity Read ↗

ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.Semantic proximity Read ↗

Decreased HER2 expression in endometrial cancer following anti‐HER2 therapySemantic proximity Read ↗

Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.Semantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies.Semantic proximity Read ↗

Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.Semantic proximity Read ↗

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.Semantic proximity Read ↗

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumorsSemantic proximity Read ↗

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.Semantic proximity Read ↗

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumorsSemantic proximity Read ↗

Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.